AMPH shows mixed operational performance with strong balance sheet growth but declining profitability due to a dramatic 1,371% spike in interest expense.
The company successfully launched three new FDA-approved products in 2025-2026, demonstrating strong pipeline execution and regulatory momentum. However, the massive increase in interest expense suggests significant new debt financing that is materially impacting profitability despite continued business growth.
AMPH's balance sheet strengthened with current assets growing 19% and cash increasing 12%, while inventory buildup of 15% supports new product launches. However, profitability deteriorated significantly with net income falling 39% and operating income down 32%, driven primarily by interest expense spiking from $1.8M to $27.2M. The combination of reduced operating cash flow (-27%) and continued share buybacks suggests the company is managing through a period of heavy debt-financed growth investments.
Interest expense surged 1371.2% — significant debt increase or rising rates materially impacting earnings.
Net income declined 38.5% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Current assets grew 19.1% — improving short-term liquidity or inventory/receivables build.
R&D investment increased 16.1% — signals commitment to future product development, though near-term margin impact.
Inventory built 15.1% — monitor whether demand supports this build or if write-downs may follow.
Cash grew 12.2% — improving liquidity position supports investment and shareholder returns.
Buyback activity reduced 11.6% — capital being redeployed elsewhere or cash conservation underway.
Equity base grew 10.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →